Core Insights - Yunnan Betaini Biotechnology Group Co., Ltd. announced an investment of 50 million yuan as a limited partner in the establishment of a 1 billion yuan Wuxi Jinyu Maowu Medical Health Industry Investment Partnership [1] - The fund will focus on investment areas including consumer healthcare, wellness, medical aesthetics, special medical and functional foods, pharmaceuticals, medical devices, and AI pharmaceuticals [1][3] - Betaini's investment strategy is aimed at addressing the slowdown in its main business growth, as evidenced by a projected decline in net profit of around 30% for 2023 and 2024 [5][6] Investment Activities - Since 2022, Betaini has participated in multiple industry investment funds, including a 100 million yuan investment in Hangzhou Sequoia Shengheng Equity Investment Partnership in June 2022 and another 100 million yuan in Nanjing Jianye Sanzheng Equity Investment Partnership in April 2023 [3] - The company has made at least 12 investment events covering various fields such as pharmaceuticals, medical devices, and skincare since 2022 [3] Financial Performance - As of June 30, 2023, Betaini reported a decline in both revenue and net profit, with total revenue of 236.77 million yuan and a net profit of 44.06 million yuan, reflecting a negative growth trend [6] - The company's net profit is projected to decline by approximately 30% in both 2023 and 2024, indicating challenges in maintaining profitability [5][6] Industry Context - The beauty and cosmetics industry is increasingly engaging in investment activities, with major companies like Proya, Marubi, and Water Sheep also establishing investment funds and making substantial investments [6] - The competitive landscape in the beauty industry is evolving, with a focus on building an ecosystem for sustainable growth through capital strategies [7]
上半年业绩不佳，贝泰妮靠投资过冬？